Physician profile
Brian D Loftus
NPI 1912983511
$193,538.39
in general payments reported to CMS, 2019-2025
34 companies · $6,606 in 2025
The $6,606 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $42K · 2021: $53K · 2022: $42K · 2023: $4,242 · 2024: $1,385 · 2025: $6,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,191 · Food and Beverage: $4,010 · Education: $31.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,191.19 |
| Food and Beverage | $4,009.85 |
| Education | $31.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $59,784.74 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Abbvie INC. | $24,854.73 | 2021-2025 | |
| Impel Pharmaceuticals INC. | $18,799.73 | 2022-2023 | Trudhesa |
| Allergan, INC. | $17,651.38 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16,413.85 | 2022 | |
| Lundbeck LLC | $15,304.55 | 2020-2025 | Vyepti |
| Amgen INC. | $13,394.38 | 2019-2023 | Aimovig |
| Biodelivery Sciences International, INC. | $10,286.74 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $9,994.95 | 2021 | |
| Pfizer INC. | $1,304.38 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,176.38 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $999.68 | 2022 | |
| Biogen, INC. | $766.42 | 2019-2024 | Tysabri, Vumerity |
| Lilly USA, LLC | $696.05 | 2019-2024 | Emgality, Kisunla |
| Sk Life Science, INC. | $410.97 | 2020-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $331.12 | 2020-2025 | Valtoco |
| Genentech USA, INC. | $234.31 | 2019-2023 | Ocrevus |
| Tg Therapeutics, INC. | $232.22 | 2023-2025 | |
| Emd Serono, INC. | $169.77 | 2019-2024 | Mavenclad |
| Scilex Pharmaceuticals INC. | $136.13 | 2023-2025 | Ztlido |
| Boston Scientific Corporation | $118.74 | 2019 | |
| Impel Pharmaceuticals LLC | $70.12 | 2024-2025 | Trudhesa |
| Axsome Therapeutics, INC. | $58.70 | 2025 | Symbravo |
| Livanova USA, INC. | $55.26 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Tonix Medicines, INC. | $44.45 | 2025 | Zembrace Symtouch |
| Grt US Holding, INC. | $44.30 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $35.55 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.05 | 2022-2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $28.81 | 2025 | Brekiya |
| Greenwich Biosciences, INC. | $27.45 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $25.06 | 2019 | |
| Merz North America, INC. | $24.39 | 2019 | |
| Medtronic, INC. | $17.29 | 2023 | Activa PC |
| Upsher-Smith Laboratories LLC | $15.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Loftus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.